Connor, Clark & Lunn Investment Management Ltd.

Position in ARVN — Arvinas, Inc.

CIK 1596800 VANCOUVER, A1

Position in ARVN

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$1,388,235

-$10,689 QoQ

Shares Held

167,056

+26.6% QoQ

Ownership

0.255%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#46

of 198 holders

Holding Since

Sep 2021

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $650,455,382 across 105 Biotechnology names. ARVN ranks #57 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,388,235	167,056	+26.6%	Shares	Sole	2026-08-13
2026-03-31	$1,398,924	131,974	+29.6%	Shares	Sole	2026-05-11
2025-12-31	$1,207,798	101,838	+217.2%	Shares	Sole	2026-02-10
2025-09-30	$273,517	32,103	-62.8%	Shares	Sole	2025-11-13
2025-06-30	$634,454	86,203	+115.1%	Shares	Sole	2025-08-07
2023-06-30	$994,686	40,076	-71.6%	Shares	Sole	2023-08-10
2023-03-31	$3,854,606	141,091	-18.2%	Shares	Sole	2023-05-10
2022-12-31	$5,900,027	172,465	-10.0%	Shares	Sole	2023-02-10
2022-09-30	$8,529,177	191,710	+56.0%	Shares	Sole	2022-11-10
2022-06-30	$5,174,039	122,928	+53.0%	Shares	Sole	2022-08-05
2022-03-31	$5,407,555	80,350	+18.0%	Shares	Sole	2022-05-12
2021-12-31	$5,590,941	68,066	+121.1%	Shares	Sole	2022-02-10
2021-09-30	$2,529,993	30,786	—	Shares	Sole	2021-11-12
No filing history on record for this holder in this stock.